🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Mette Nygaard Einfeldt

Novo Nordisk (Denmark)

ORCID: 0000-0003-2427-2601

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial”.

Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial

Nature Medicine(2023)10.1038/s41591-023-02526-x

N/A

5.5DataRank · unranked

193 citations

Dalane W. Kitzman, Melanie J. Davies, Søren Rasmussen, Eric Barros, Javed Butler +23 more

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

The Lancet(2024)10.1016/s0140-6736(24)00469-0

N/A

5.3DataRank · unranked

335 citations

Sanjiv J. Shah, Mark C. Petrie, Barry A. Borlaug, Steen Z. Abildstrøm, Melanie J. Davies +27 more

Semaglutide and Exercise Function in Obesity-Related HFpEF

JACC Heart Failure(2025)10.1016/j.jchf.2025.102660

N/A

0.328DataRank · unranked

5 citations

Dalane W. Kitzman, Shachi Patel, Khaja Chinnakondepalli, Javed Butler, Melanie J. Davies +9 more